Boehringer, Perosphere Anticoagulant Antidotes Advance At AHA
Executive Summary
At a time when demand for anticoagulant antidotes is high, the 2013 AHA meeting featured the first human data for two new reversal agents from Boehringer Ingelheim and Perosphere. Perosphere will be pursuing “breakthrough therapy” status with FDA for its intravenous small molecule candidate PER977.